17-Hydroxyprogesterone Ester-Containing Oral Compositions and Related Methods
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 6 of these applications claim priority to application 13/193,571, filed Jul 28, 2011. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 8,951,996 | 17-Hydroxyprogesterone Ester-Containing Oral Compositions and Related Methods In force · High confidence | Lipocine Inc. | In force | High confidence | ||
| US 9,358,298 | 17-Hydroxyprogesterone Ester Containing Oral Compositions and Related Methods In force · High confidence | Lipocine Inc. | In force | High confidence | ||
| US 9,358,299 | 17-Hydroxyprogesterone Ester-Containing Oral Compositions and Related Methods In force · High confidence | Lipocine Inc. | In force | High confidence | ||
| US 9,364,547 | 17-Hydroxyprogesterone Ester Containing Oral Compositions and Related Methods In force · High confidence | Lipocine Inc. | In force | High confidence | ||
| US 9,399,069 | 17-Hydroxyprogesterone Ester Containing Oral Compositions and Related Methods In force · High confidence | Lipocine Inc. | In force | High confidence | ||
| US 10,022,384 | 17-Hydroxyprogesterone Ester-Containing Oral Compositions and Related Methods In force · Medium confidence | Lipocine Inc. | In force | Medium confidence | ||
| US 11,471,470 | 17-Hydroxyprogesterone Ester-Containing Oral Compositions and Related Methods In force · Medium confidence | Lipocine Inc. | In force | Medium confidence | ||
| US 10,709,716 | 17-Hydroxyprogesterone Ester-Containing Oral Compositions and Related Methods Lapsed Jul 14, 2024 on the fee record Medium confidence | Lipocine Inc. | Lapsed Jul 14, 2024 on the fee record | Medium confidence | ||
| Application 15/266,206 | 17-Hydroxyprogesterone Ester-Containing Oral Compositions and Related Methods Abandoned Abandoned Sep 17, 2018 | Lipocine Inc. | Abandoned | Abandoned Sep 17, 2018 | ||
| Application 16/010,188 | 17-Hydroxyprogesterone Ester-Containing Oral Compositions and Related Methods Abandoned Abandoned Apr 2, 2019 | Lipocine Inc. | Abandoned | Abandoned Apr 2, 2019 |
10 of 10 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
7 of these are in force and held by Lipocine Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.